麻豆传媒

Japanese trial supports use but event risk might be low enough to suggest a different strategy

Question of when to test involves navigating patient privacy, legal, ethical concerns

Device yields 10% absolute reduction in acute kidney injury within a week of surgery

Reduction in total shock burden is not proven, however

Study lays out common gaps in evidence both before and after approval

Meta-analysis suggested lower stroke risk, but more definitive trial is not expected until 2032

Continued OAC failed to meet noninferiority in POPular PAUSE TAVI

Trial paints a fuller picture of risk-benefit in complex patient population

RESHAPE-HF2 has provocative implications for a wider pool of TEER candidates

First randomized trial debunks common practice of tight control

Either choice is "acceptable" based on randomized study

Sex should factor into tailoring of postoperative care, research suggests

PD-L1 checkpoint inhibitor approved for use in NSCLC before and after surgery

ACE-PROTAVI trial tested upfront vs selective use of heparin reversal agent